Dermorphin 5mg*10vials*1kits – Best Eeffect Hiqh Purity Peptides Product

Description

Dermorphin >99% Purity | Mu-Opioid Receptor Agonist

Mechanism Overview

The biochemical activity of Dermorphin is defined by its extraordinary selectivity and potency as an agonist for the mu-opioid receptor (MOR). Unlike many endogenous peptides, its D-Ala2 configuration prevents rapid degradation by aminopeptidases. The primary mechanism involves the peptide binds to the MOR, initiating a G-protein coupled signaling cascade that inhibits adenylyl cyclase activity. This defines the first semantic triple: [Dermorphin activates MOR]. Following this, this activation leads to the closure of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters. This establishes the second triple: [Dermorphin inhibits neurotransmitter release]. Finally, the signaling pathway simultaneously opens inward-rectifying potassium channels, resulting in cellular hyperpolarization. This forms the third triple: [Dermorphin induces hyperpolarization]. Quantitatively, Dermorphin exhibits a binding affinity (Ki) of approximately 0.45 nM for the mu-receptor, demonstrating nearly 100-fold selectivity over delta-opioid receptors. Research models indicate that Dermorphin is approximately 30-40 times more potent than morphine as an analgesic when evaluated in central nervous system distribution assays.

Compound Background

Dermorphin is a natural heptapeptide originally isolated from the skin of South American frogs, specifically characterized by its unique inclusion of a D-Alanine residue at the second position. This D-amino acid substitution confers extreme resistance to enzymatic hydrolysis, allowing the peptide to maintain structural integrity within complex biological environments. [Dermorphin targets MOR].

Product Specifications

• CAS Number: 77614-16-5
• Molecular Formula: C40H50N8O10
• Molecular Weight: 802.87 Da
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Known Effects

• Potent Analgesic Response: Experimental data suggests profound antinociceptive effects during research phases, significantly exceeding the potency of standard alkaloids.
• Modulation of Gastrointestinal Motility: Experimental findings suggest a marked reduction in intestinal transit speed through localized receptor activation.
• Sedative Properties: According to research documentation, research models often observe deep state relaxation and decreased locomotor activity.
• Respiratory Rate Influence: Cumulative findings indicate a dose-dependent reduction in respiratory frequency, typical of high-affinity mu-agonists.
• Endocrine Interaction: Research models have noted transient changes in the release of pituitary hormones following systemic administration.

In Brief:
Dermorphin represents a highly potent research tool for investigating selective mu-opioid signaling and the evolution of D-amino acid peptide stability.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.